Form 4: Greenwich LifeSciences VP Acquires 800 Shares of GLSI
SEC Form 4 Filing
Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, purchased 800 shares of GLSI at $13.85 per share on August 12, 2024.
Summary
- On August 12, 2024, Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, acquired 800 shares of the company's common stock.
- The purchase price was $13.85 per share.
- Following the transaction, Thompson directly owns 263,148 shares of Greenwich LifeSciences.
Sentiment
Score: 6
Explanation: Insider buying is generally viewed as a positive sign, but the small number of shares purchased by the VP is unlikely to have a significant impact on the company's overall valuation.
Positives
- The purchase of shares by a company insider can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by investors as it can provide insights into a company's performance and future prospects. Form 4 filings are a routine part of this monitoring process.
Stakeholder Impact
- The purchase of shares by a company insider may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of transaction: Jaye Thompson purchased 800 shares of GLSI. |
| 09/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.